.Pharmacolibrary.Drugs.C_CardiovascularSystem.C07A_BetaBlockingAgents.C07AG02_Carvedilol.Carvedilol

Information

Carvedilol is a non-selective beta-adrenergic blocker with alpha-1 blocking activity, primarily used for the treatment of heart failure, hypertension, and left ventricular dysfunction after myocardial infarction. It is an approved and widely used cardiovascular agent.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after single oral dose administration.

References

1. Saito, M, et al., & Ogata, H (2010). Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure. Biological & pharmaceutical bulletin 33(8) 1378–1384. DOI:10.1248/bpb.33.1378 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20686235

2. Othman, AA, et al., & Fossler, MJ (2007). Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. The AAPS journal 9(2) E208–E218. DOI:10.1208/aapsj0902023 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17614362

3. Wermeling, DP, et al., & Boyle, DA (1994). Effects of long-term oral carvedilol on the steady-state pharmacokinetics of oral digoxin in patients with mild to moderate hypertension. Pharmacotherapy 14(5) 600–606. PUBMED:https://pubmed.ncbi.nlm.nih.gov/7997394

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)